
(2/2/07)

PTO/SB/08B (8/03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Substitute for form 1449/PTO COMPLETE IF KNOWN **Application Number** 10/648,593 Filing Date 08/26/2003 **INFORMATION DISCLOSURE** First Named Inventor **FEI HUANG** STATEMENT BY APPLICANT(S)
(use as many sheets as necessary) Art Unit 1652 SWOPE, SHERIDAN Examiner Name Attorney Docket Number D0273 NP Sheet 1

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article(when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Check box if English language Translation is attached			
5	AA	Sixth Annual Conference – Targeted Therapies in the Treatment of Breast Cancer, July 2003; "Development of Src Kinase Inhibitors for the Treatment of Breast Cancer", Arthur P. DeCillis, Group Director, Oncology Clinical Development, Bristol-Myers Squibb Oncology				
		·				
_						
			,			

Examiner SHERIDAN SWOPE, PH.D. Signature PRIMARY EXAMINER	Date Considered	JAN 2 6 2008
---	--------------------	--------------

^{*}EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

ART UNIT: 1656

FEI HUANG, ET AL.

EXAMINER: SWOPE, SHERIDAN

APPLICATION NO: 10/648,593

FILED: 08/26/2003

FOR: IDENTIFICATION OF POLYNUCLEOTIDES FOR PREDICTING ACTIVITY OF COMPOUNDS THAT INTERACT WITH AND/OR MODULATE PROTEIN TYROSINE KINASES AND/OR PROTEIN TYROSINE KINASE PATHWAYS IN BREAST CELLS

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT ACCOMPANYING AN RCE

Sir:

This paper is being filed concurrently with an RCE application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the reference cited on the attached form PTO-1449.

In accordance with 37 C.F.R. § 1.98(a)(2)(iii), applicants wish to call the Examiner's attention to the following related application:



Attorney Docket No.	Application No.	Filing Date	Status
10719 PCT	PCT/US2006/060776	11/10/2006	Pending